OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

January 31, 2004

Study Completion Date

March 31, 2014

Conditions
Kidney Cancer
Interventions
DRUG

OSI-774

150mg PO, days 1-28, cycle repeated every 28 days

DRUG

Bevacizumab

10mg/kg, IV infusion, Days 1 and 15, 28 day cycles

Trial Locations (2)

49503

Grand Rapids Oncology Program, Grand Rapids

70809

Medical Oncology LLC, Baton Rouge

Sponsors
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER